Compare LGN & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LGN | ICUI |
|---|---|---|
| Founded | 1963 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.9B |
| IPO Year | N/A | 1995 |
| Metric | LGN | ICUI |
|---|---|---|
| Price | $73.81 | $129.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 4 |
| Target Price | $54.43 | ★ $182.25 |
| AVG Volume (30 Days) | ★ 2.0M | 229.1K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.62 |
| EPS | N/A | ★ 0.03 |
| Revenue | N/A | ★ $2,231,262,000.00 |
| Revenue This Year | $53.66 | N/A |
| Revenue Next Year | $11.99 | $4.46 |
| P/E Ratio | ★ N/A | $4,201.67 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $28.31 | $107.02 |
| 52 Week High | $70.35 | $160.29 |
| Indicator | LGN | ICUI |
|---|---|---|
| Relative Strength Index (RSI) | 75.38 | 51.45 |
| Support Level | $42.97 | $121.48 |
| Resistance Level | N/A | $133.62 |
| Average True Range (ATR) | 3.47 | 4.24 |
| MACD | 1.51 | 1.15 |
| Stochastic Oscillator | 95.39 | 89.18 |
Legence Corp is a provider of engineering, installation and maintenance services for mission-critical systems in buildings. It focuses on high-growth sectors that have technically demanding buildings, including technology, life sciences, healthcare and education. The company specializes in designing, fabricating and installing complex HVAC, process piping and other mechanical, electrical and plumbing (MEP) systems for new facilities and upgrading HVAC, lighting and building controls in existing facilities to make them more energy efficient and sustainable.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.